Qi Wang

Qi Wang is an Honorary Research Fellow and Senior Research Associate at the Norwich Medical School, University of East Anglia, affiliated with the Department of Metabolic Health. Their research focuses on cancer therapy, nanotechnology, and drug delivery systems, with a particular emphasis on natural compounds like isothiocyanates and nanoparticle-based treatments. Wang has contributed to projects funded by organizations such as the Cancer Prevention Research Trust and Prostate Cancer UK, exploring synergistic drug combinations and anticancer mechanisms.

Key research areas include targeted drug delivery for triple-negative breast cancer, antimicrobial wound dressings, and the development of nano-formulated anti-rheumatic agents. Their work spans preclinical validation of nanoparticles, dietary interventions for cancer prevention, and material science innovations in silicon-based biomedical applications. Collaborations with institutions like the University of Essex and international researchers highlight interdisciplinary strengths in oncology, nanomedicine, and public health.

Notable projects include the CPRT-funded study on plant chemicals and cancer prevention (2024–2027) and the RA Funding ICR Collaboration targeting prostate cancer (2017–2018). Publications emphasize translational research, with recent contributions to Frontiers in Nutrition, International Journal of Biological Macromolecules, and Cancers.

Grants and funding reflect a focus on bridging fundamental science and clinical applications, while ongoing projects aim to advance nanoparticle-based therapies and dietary interventions to combat cancer and inflammation. Wang’s labs and teams are embedded within Norwich Medical School’s collaborative environment, fostering innovation in metabolic health and oncology research.